Collectively, these data demonstrate that limiting TGF-β activity through antagonizing the angiotensin II type 1 receptor by losartan effectively ameliorates the RDEB phenotype in vivo. Here, AGTR1 is linked to recessive dystrophic epidermolysis bullosa.